J&J reportedly sought help from rivals after blood clot concerns emerged

Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday, citing people familiar with the situation. Only AstraZeneca agreed, according to the WSJ.

J&J also wanted to build an informal alliance with its competitors that it hoped would allow the industry to speak with one voice about the safety of the vaccines and address any public concerns about the blood-clot cases, the Journal reported. In a statement to CNN on Friday, a Pfizer (PFE) spokesperson declined to comment on the specifics of the WSJ report. "Pfizer embraces opportunities for scientific exchange when we can make a meaningful contribution that is not being represented by other groups or regulators," the spokesperson said. "We have and will continue to collaborate with other vaccine makers as appropriate as we all fight against this deadly pandemic."